| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
207,851,000 |
| Market
Cap: |
11.62(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$31.86 - $59.82 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Catalent is a holding company. Through its subsidiaries, Co. has two operating and reporting segments: Biologics and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells; and vaccines. The Pharma and Consumer Health segment comprises Co.'s capabilities for oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,000 |
1,000 |
| Total Buy Value |
$0 |
$0 |
$49,980 |
$49,980 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
387 |
387 |
13,187 |
116,582 |
| Total Sell Value |
$21,749 |
$21,749 |
$618,484 |
$11,151,362 |
| Total People Sold |
1 |
1 |
14 |
18 |
| Total Sell Transactions |
1 |
1 |
27 |
69 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gunther Scott |
SVP, Quality & Reg. Affairs |
• – – |
2024-03-15 |
4 |
AS |
$56.20 |
$21,749 |
D/D |
(387) |
29,506 |
|
-1% |
|
| Kreuzburg Christa |
Director |
– • – |
2024-01-25 |
4 |
D |
$50.41 |
$26,364 |
D/D |
(523) |
18,283 |
|
- |
|
| Hatzfeld Michael |
Chief Accounting Officer |
• – – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,908 |
7,908 |
|
- |
|
| Gennadios Aristippos |
Group Pres. Pharma & Consumer |
• – – |
2023-12-08 |
4 |
D |
$37.18 |
$13,645 |
D/D |
(367) |
96,496 |
|
- |
|
| Gennadios Aristippos |
Group Pres. Pharma & Consumer |
• – – |
2023-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,505 |
96,863 |
|
- |
|
| Hopson Ricky |
Pres. Clinical Dev Supply Div |
• – – |
2023-12-08 |
4 |
D |
$37.18 |
$9,518 |
D/D |
(256) |
22,018 |
|
- |
|
| Hopson Ricky |
Pres. Clinical Dev Supply Div |
• – – |
2023-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
747 |
22,274 |
|
- |
|
| Maselli Alessandro |
President & CEO |
• • – |
2023-12-08 |
4 |
D |
$37.18 |
$71,534 |
D/D |
(1,924) |
87,938 |
|
- |
|
| Maselli Alessandro |
President & CEO |
• • – |
2023-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
3,761 |
89,862 |
|
- |
|
| Gunther Scott |
SVP, Quality & Reg. Affairs |
• – – |
2023-12-08 |
4 |
D |
$37.18 |
$9,295 |
D/D |
(250) |
29,893 |
|
- |
|
| Gunther Scott |
SVP, Quality & Reg. Affairs |
• – – |
2023-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,023 |
30,143 |
|
- |
|
| Barber Michael J |
Director |
– • – |
2023-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,993 |
13,389 |
|
- |
|
| Stahl Jack L |
Director |
– • – |
2023-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,993 |
43,321 |
|
- |
|
| Damelio Frank A |
Director |
– • – |
2023-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,993 |
7,972 |
|
- |
|
| Morel Donald E Jr |
Director |
– • – |
2023-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,993 |
65,455 |
|
- |
|
| Ryan Michelle R |
Director |
– • – |
2023-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,993 |
8,972 |
|
- |
|
| Classon Rolf A |
Director |
– • – |
2023-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,993 |
43,321 |
|
- |
|
| Barg Steven |
Director |
– • – |
2023-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,993 |
7,711 |
|
- |
|
| Lucier Gregory T |
Director |
– • – |
2023-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,993 |
32,251 |
|
- |
|
| Crane Rosemary A |
Director |
– • – |
2023-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,993 |
23,873 |
|
- |
|
| Balachandran Madhavan |
Director |
– • – |
2023-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,993 |
27,441 |
|
- |
|
| Kreuzburg Christa |
Director |
– • – |
2023-10-27 |
4 |
D |
$39.32 |
$48,953 |
D/D |
(1,245) |
18,806 |
|
- |
|
| Kreuzburg Christa |
Director |
– • – |
2023-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,993 |
20,051 |
|
- |
|
| Flynn Karen |
Director |
– • – |
2023-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,993 |
24,339 |
|
- |
|
| Carroll J Martin |
Director |
– • – |
2023-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,993 |
28,071 |
|
- |
|
821 Records found
|
|
Page 1 of 33 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.12 (0.22%) 
